Evidence map›Paper›PMID 41334671›Full record

ArticleHead & neck2026

Hypofractionated Spot Scanning Proton Therapy for Head and Neck Mucosal Melanoma: A Retrospective Analysis With Quality-of-Life Outcome.

Koichiro Nakajima, Hiromitsu Iwata, Gaku Takano, Daiki Kojima, Yukiko Hattori, Yusuke Tsuzuki, Shuou Sudo, Kensuke Hayashi, Toshiyuki Toshito, Hideo Fukano and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Koichiro NakajimaDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.ORCID 0000-0002-2306-7836
Hiromitsu IwataDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.ORCID 0000-0001-9809-9800
Gaku TakanoDepartment of Otorhinolaryngology, Nagoya City University West Medical Center, Nagoya, Japan.
Daiki KojimaDepartment of Oral and Maxillofacial Surgery, Nagoya City University West Medical Center, Nagoya, Japan.
Yukiko HattoriDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Yusuke TsuzukiDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.ORCID 0009-0000-2335-3309
Shuou SudoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Kensuke HayashiDepartment of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Toshiyuki ToshitoDepartment of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya City West Medical Center, Nagoya, Japan.
Hideo FukanoDepartment of Oral and Maxillofacial Surgery, Nagoya City University West Medical Center, Nagoya, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya, Japan.
Akio HiwatashiDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Funding

Japan Society for the Promotion of Science 24K18835
6 · The paper itself

Abstract

objectiveTo evaluate clinical outcomes and quality of life (QOL) following hypofractionated spot-scanning proton therapy (SSPT) for head and neck malignant mucosal melanoma (HNMM).

methodsThis retrospective study included 39 patients treated with SSPT (60-64 Gy[RBE] in 15-16 fractions) between 2013 and 2023. Endpoints included overall survival (OS), local control (LC), progression-free survival (PFS), toxicities, and QOL.

resultsMost tumors were located in the sinonasal cavity (n = 32). Surgery was performed in 8 patients; 19 received immune checkpoint inhibitors post-SSPT. The 3-year OS, LC, and PFS were 50%, 83%, and 30%, respectively. Larger tumor volumes (≥ 20 cm

conclusionSSPT provides favorable LC with acceptable toxicity. Effective systemic therapies are needed to improve long-term outcomes.

Indexed as

Head and Neck NeoplasmsMelanomaProton TherapyQuality of LifeRadiation Dose HypofractionationAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment Outcomehead and neckmelanomaproton therapyquality of lifespot scanning

Identifiers

PMID41334671
PMCPMC13055425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.